Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Trial StartIcovamenibSemaglutidePositive

AI Analysis

Summary

Biomea Fusion announced dosing of the first patient in the OPAL Study evaluating icovamenib in combination with low-dose semaglutide for obesity, assessing effects on physical function, body weight, composition, muscle health, and metabolic outcomes.

Clinical Trial Data

Outcome Details

First patient dosed in OPAL Study

Importance:5/10

Sentiment:

0.50

obesitycombination therapyclinical trialicovamenibsemaglutide

Related Companies

$IBO $HIT $TRAX

Read the original article

Published by GlobeNewswire Pharma on August 13, 2026 11:00 AM

Read Original